UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 12, 2004 (October 11, 2004)
Chiron Corporation
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-12798 |
|
94-2754624 |
||
|
(State or other |
|
(Commission |
|
(IRS Employer |
||
|
|
|
|
||||
|
4560 Horton Street, Emeryville, CA |
|
94608 |
||||
|
(Address of principal executive offices) |
|
(Zip Code) |
||||
|
|
|
|
||||
|
Registrant’s telephone number, including area code (510) 655-8730 |
||||||
|
|
||||||
|
N/A |
||||||
|
(Former name or former address, if changed since last report) |
||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On October 11, 2004, Chiron Corporation received a grand jury subpoena issued by the U.S. Attorney’s Office for the Southern District of New York requesting production of certain documents and materials relating to Chiron’s Fluvirin influenza virus vaccine and the suspension by the United Kingdom’s Medicines and Healthcare products Regulatory Agency of Chiron’s license to manufacture the Fluvirin vaccine. Chiron intends to fully cooperate with the U.S. Attorney’s office in its investigation.
# # #
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CHIRON CORPORATION |
|
||
|
|
(Registrant) |
|
||
|
|
|
|||
|
|
|
|||
|
Date: October 11, 2004 |
By: |
/s/ Ursula B. Bartels |
|
|
|
|
|
Ursula B. Bartels |
||
|
|
|
Vice President and General Counsel |
||
3